60 Degrees Pharmaceuticals, Inc.
SXTP
Rank in Stocks
#32188
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated... 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Share Price
$0.5462
Last synced: 2026-11-09
Market Cap
$1.92M
Change (1 day)
-8.19%
Change (1 year)
-89.25%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade 60 Degrees Pharmaceuticals, Inc. (SXTP)
Category
Healthcare
Operating Margin for 60 Degrees Pharmaceuticals, Inc. (SXTP)
Operating Margin as of November 2026 TTM: -774.90%
According to 60 Degrees Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is -774.90%. At the end of 2025 the company had an operating margin of -771.64%.
Operating Margin history for 60 Degrees Pharmaceuticals, Inc. from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -774.90% | 0.42% |
| 2025 | -771.64% | -51.74% |
| 2024 | -1,598.97% | -21.34% |
| 2023 | -2,032.78% | 159.21% |
| 2022 | -784.22% | 709.48% |
| 2021 | -96.88% | 405.37% |
| 2020 | -19.17% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.81% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about 60 Degrees Pharmaceuticals, Inc.'s operating margin
What is 60 Degrees Pharmaceuticals, Inc.'s operating margin?
60 Degrees Pharmaceuticals, Inc.'s operating margin is -774.90%, as of Nov 2026.
What was 60 Degrees Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, 60 Degrees Pharmaceuticals, Inc.'s operating margin was -771.64%, compared with -1,598.97% in 2024.
How has 60 Degrees Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, 60 Degrees Pharmaceuticals, Inc.'s operating margin was highest in 2020 (-19.17%) and lowest in 2023 (-2,032.78%).
How does 60 Degrees Pharmaceuticals, Inc.'s operating margin compare with similar companies?
60 Degrees Pharmaceuticals, Inc.'s operating margin (-774.90%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.